ValueAct Capital, LLC
http://www.valueact.com/ValueAct Capital, LLC is a San Francisco based hedge fund. The firm offers its services to high net worth individuals and institutions while investing in the public equity and hedging markets of the United States. VAC primarily invests in share re-purchase programs, public market recapitalizations, de-leveraging equity infusions, off-balance sheet financings, and going-private transactions. The fund invests in companies with market capitalizations ranging from $150 million to $1.5 billion and typically invests $25 million to $100 million per investment. In addition, VAC sometimes invests in private companies depending on the growth opportunities.
View Older Stories View More Recent Stories
-
Activist investors take a beating in energy price rout
-
Activist investors take a beating in energy price rout
-
Activist investors take a beating in energy price rout
-
Activist investors take a beating in energy price rout
-
Activist investors take a beating in energy price rout
-
Activist investors take a beating in energy price rout
-
Form 4 CBRE GROUP, INC. For: Feb 11 Filed by: ValueAct Holdings GP, LLC
-
Form 13F-HR ValueAct Holdings, L.P. For: Dec 31
-
Form 4 CBRE GROUP, INC. For: Feb 08 Filed by: ValueAct Holdings, L.P.
-
Form 4 ADOBE SYSTEMS INC For: Jan 29 Filed by: ValueAct Holdings GP, LLC
-
Fitch: Activists Change Tack with US Financial Institutions
-
Form 4 MICROSOFT CORP For: Jan 29 Filed by: ValueAct Co-Invest Master Fund, L.P.
-
Rolls-Royce cuts senior manager jobs in savings drive
-
Activist Insight and Schulte Roth & Zabel Release The Activist Investing Annual Review 2016
-
Form 4 ADOBE SYSTEMS INC For: Jan 21 Filed by: ValueAct Capital Management, L.P.
-
UPDATE: American Express (AXP) Taps Session Low; ValuaeAct Said to Liquidate Stake
-
Valeant names interim CEO; timing of Pearson's return unknown
-
Valeant selects trio to fill in for ailing CEO; shares dive
-
Valeant Pharma (VRX) Confirms CEO J. Michael Pearson on Medical Leave
-
Valeant Announces J. Michael Pearson Will Be On Medical Leave of Absence
-
Activist pressure helps reshape U.S. corporates, from Yahoo to Dow
-
Motorola Solutions to buy UK's Airwave for $1.24 billion
-
Form 4 MICROSOFT CORP For: Dec 01 Filed by: ValueAct Co-Invest Master Fund, L.P.
-
Microsoft holds annual shareholder meeting
-
Form 4 ValueAct Holdings GP, For: Nov 25 Filed by: Spivy Gregory P
-
Peltz's activist fund Trian to end quarterly redemptions: sources
-
Exclusive: ValueAct gains for the year wiped out by Valeant loss
-
Form 4 MSCI Inc. For: Nov 18 Filed by: ValueAct Capital Master Fund, L.P.
-
Update -- Willis Group and Towers Watson Agree Amended Terms to the Proposed Merger of Equals
-
Willis Group and Towers Watson Agree Amended Terms to the Proposed Merger of Equals
-
ValueAct Capital Management's 13F Shows New Stake in Towers Watson (TW), Fox (FOX), (more...)
-
Form 13F-HR ValueAct Holdings, L.P. For: Sep 30
-
Valeant Pharma (VRX) on Watch After Larger Holder Frees Up $1B
-
ValueAct Sells 18.65M Microsoft (MSFT) Shares
-
ValueAct Capital Discloses Sale of Shares of Microsoft Corporation.
-
Form 4 MICROSOFT CORP For: Nov 10 Filed by: ValueAct Holdings GP, LLC
-
ValueAct Disagrees with ISS Recommendation on Towers Watson (TW) Merger
-
ValueAct Capital Voices Strong Disagreement with ISS Voting Recommendations for Towers Watson Stockholders
-
Motorola Solutions shareholder ValueAct says shares undervalued
-
Form 4 MSCI Inc. For: Nov 05 Filed by: ValueAct Capital Master Fund, L.P.
-
Ackman backs Valeant CEO as shares tumble to 2-1/2 year lows
-
Valeant (VRX) In Free Fall as Large Holders May Finally Be Crying Uncle
-
Ackman Stocks Trade Lower on Valeant (VRX) Free-Fall
-
Bloomberg's "The Year Ahead: 2016" to Feature Apple's Angela Ahrendts, Bank Of America's Brian Moynihan, Credit Suisse's Tidjane Thiam, Fashion Legend Diane von Furstenberg and More
-
Valeant says Philidor pharmacy shutting down as it cuts ties
-
CVS, Express Scripts drop Valeant's Philidor; stock dives
-
ValueAct rallies Valeant investors as company fends off attack: source
-
ValueAct said in outreach to other Valeant Pharma (VRX) investors - Reuters
-
Drugmaker Valeant raises detailed defense but doubts remain
-
Valeant Pharma (VRX) Adds ValueAct's Morfit as Director

